Journal of Child and Adolescent Psychopharmacology

SJR Rank #9,522H-index: 100SJR: 0.618Best quartile: Q2
Journal website: aims, scope and author guidelines
Publisher

Mary Ann Liebert Inc.

Country

United States

Type

journal

SJR by Edition

2022202500.20.40.60.8

Subject Categories

  • Pediatrics, Perinatology and Child HealthQ2
  • Pharmacology (medical)Q2
  • Psychiatry and Mental HealthQ2

Areas: Medicine

Most published research topics

Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional DevelopmentBipolar Disorder and TreatmentAutism Spectrum Disorder ResearchSchizophrenia research and treatmentPharmaceutical studies and practicesObsessive-Compulsive Spectrum DisordersTreatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorElectroconvulsive Therapy Studies

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs055110165220

Documents per Year

202220250306090120

Detailed Information

ISSN

1044-5463, 1557-8992

SJR Best Quartile

Q2

Region

Northern America

Citations per Document (2 years)

1.41

References per Document

30.34

Coverage

1990-2026

Scope

Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more. Journal of Child and Adolescent Psychopharmacology coverage includes: New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.

Metrics from SCImago Journal Rank 2025. View on SCImago